FDAsafety guidance66% confidence
FDA AP — LENALIDOMIDE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Dr. Reddy's; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA213912. Sponsor: MYLAN. Submission status: AP. Submission type: SUPPL. Active ingredients: LENALIDOMIDE.
Supporting Context
- Therapeutic area
- Oncology · Small Molecule
- Sub-indication
- General
Related signal: FDA Accepts Supplement Application for Lenalidomide by Dr. Reddy's